comparemela.com
  1. Home
  2. Live Updates
  3. Janssen Cilag Gmb - Breaking News

Page 4 - Janssen Cilag Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen s Akeega receives EC approval for metastatic prostate cancer

Janssen s Akeega receives EC approval for metastatic prostate cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Martin vogelJanssen cilag gmbJanssen pharmaceutical companies of johnsonEuropean commissionJanssen pharmaceutical companiesJanssen cilag gmbh

Janssen reaches Akeega approval milestone

Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer - News - PharmaTimes

Janssen cilag gmbGerhardt attardMartin vogelUniversity college londonJanssen pharmaceutical companies of johnsonEuropean commissionJanssen pharmaceutical companiesJanssen cilag gmbh

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®. | April 21, 2023

Region flamandeUnited kingdomCity ofJanssen cilag gmbMartin vogelMagda palhotaPeter lebowitzGerhardt attardJanssen cilag gmUrology care foundationExchange commissionDrug administrationCompanies of johnsonJanssen research developmentEuropean medicines agencyUniversity college london

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com . | April 21, 2023

United kingdomRegion flamandeCity ofJanssen cilag gmbPeter lebowitzMartin vogelMagda palhotaGerhardt attardEuropean commissionUniversity college londonCompanies of johnsonJanssen cilag internationalEuropean unionDrug administrationJanssen biotech incTesaro inc

Janssen s Rybrevant yields positive data

Results from trial showed a long-term response among specific lung cancer population - News - PharmaTimes

Martin vogelJanssen cilag gmbPilar garridoEuropean lung cancer congressJanssen pharmaceutical companies of johnsonJanssen pharmaceutical companiesLung cancer congressJanssen cilag gmbhUniversidad de alcal

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.